Back to top
more

Vascular Biogenics Ltd. (VBLT)

(Delayed Data from NSDQ)

$1.28 USD

1.28
10,710

+0.01 (0.79%)

Updated May 3, 2019 03:59 PM ET

After-Market: $1.28 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug

The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.

What Makes Vascular Biogenics (VBLT) a New Buy Stock

Vascular Biogenics (VBLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 10.00% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Vascular Biogenics (VBLT) Report Negative Q3 Earnings? What You Should Know

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) Reports Q2 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -20.00% and -48.63%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Vascular Biogenics (VBLT) Report Negative Q2 Earnings? What You Should Know

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and -7.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) Reports Q4 Loss, Tops Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -15.38% and 2.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 28.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -15.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Vascular Biogenics (VBLT) Q2 Earnings Expected to Decline

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) Reports Q1 Loss, Tops Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 6.25% and 89.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Vascular Biogenics (VBLT) Q1 Earnings Expected to Decline

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -23.08% and -31.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will VBL Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in VBL.

Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -67.08%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 0.00% and -44.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -100.00% and -90.48%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Vascular Biogenics (VBLT) Report Negative Earnings Next Week? What You Should Know

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vascular Biogenics (VBLT) Reports Q4 Loss, Misses Revenue Estimates

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 41.18% and -53.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?